冠昊生物
(300238)
| 流通市值：29.83亿 | | | 总市值：29.83亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 174,516,375.45 | 93,444,027.57 | 387,749,767.9 | 293,480,433.06 |
| 营业收入 | 174,516,375.45 | 93,444,027.57 | 387,749,767.9 | 293,480,433.06 |
| 二、营业总成本 | 161,974,132.06 | 83,859,027.31 | 358,622,829.07 | 261,309,394.44 |
| 营业成本 | 41,615,833.26 | 21,826,801.12 | 88,670,267.74 | 65,461,131.78 |
| 税金及附加 | 3,424,736.66 | 1,817,625.02 | 7,457,600.58 | 4,370,483.24 |
| 销售费用 | 68,826,465.38 | 37,291,654.14 | 160,935,392.93 | 117,945,405.5 |
| 管理费用 | 30,870,171.42 | 14,177,324.89 | 57,210,995.98 | 44,580,466.84 |
| 研发费用 | 16,015,191.4 | 8,052,164.27 | 40,965,725.76 | 26,237,061.42 |
| 财务费用 | 1,221,733.94 | 693,457.87 | 3,382,846.08 | 2,714,845.66 |
| 其中:利息费用 | 1,666,148.25 | 942,466.15 | 4,035,969.72 | 2,805,431.95 |
| 其中:利息收入 | 265,772.48 | 159,041.56 | 663,463.45 | 460,993.41 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -153,040.41 | -153,040.41 | 1,894,614.62 | 191,885.2 |
| 资产处置收益 | 88,775.14 | 88,241.47 | -5,119.4 | -5,520.88 |
| 资产减值损失(新) | -285,187.29 | 7,760.08 | -1,901,987.23 | -1,576,829.59 |
| 信用减值损失(新) | -1,219,768.96 | -254,396.99 | -1,284,799.19 | -1,062,719.56 |
| 其他收益 | 2,167,158.85 | 1,427,731.84 | 2,623,865.52 | 1,723,707.23 |
| 四、营业利润 | 13,140,180.72 | 10,701,296.25 | 30,453,513.15 | 31,441,561.02 |
| 加:营业外收入 | 341,735.66 | 331,801.64 | 900,054.95 | 890,649.84 |
| 减:营业外支出 | -263,975.13 | 519,430.24 | 4,073,006.27 | 212,681.34 |
| 五、利润总额 | 13,745,891.51 | 10,513,667.65 | 27,280,561.83 | 32,119,529.52 |
| 减:所得税费用 | 6,092,162.52 | 3,311,199.98 | 12,493,291.79 | 11,690,361.99 |
| 六、净利润 | 7,653,728.99 | 7,202,467.67 | 14,787,270.04 | 20,429,167.53 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 7,653,728.99 | 7,202,467.67 | 14,787,269.94 | 20,429,167.53 |
| 终止经营净利润 | - | - | 0.1 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 13,239,784.88 | 10,162,275.45 | 24,346,028.28 | 26,718,493.89 |
| 少数股东损益 | -5,586,055.89 | -2,959,807.78 | -9,558,758.24 | -6,289,326.36 |
| 扣除非经常损益后的净利润 | 10,423,780.18 | 9,242,718.55 | 26,311,919.29 | 25,820,574.06 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.05 | 0.04 | 0.09 | 0.1 |
| (二)稀释每股收益 | 0.05 | 0.04 | 0.09 | 0.1 |
| 八、其他综合收益 | -191,767.96 | -112,033.94 | -125,555.44 | -69,791.15 |
| 归属于母公司股东的其他综合收益 | -191,767.96 | -112,033.94 | -125,555.44 | -69,791.15 |
| 九、综合收益总额 | 7,461,961.03 | 7,090,433.73 | 14,661,714.6 | 20,359,376.38 |
| 归属于母公司股东的综合收益总额 | 13,048,016.92 | 10,050,241.51 | 24,220,472.84 | 26,648,702.74 |
| 归属于少数股东的综合收益总额 | -5,586,055.89 | -2,959,807.78 | -9,558,758.24 | -6,289,326.36 |
| 公告日期 | 2026-08-29 | 2026-04-29 | 2026-03-26 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |